MYC and KRAS act as downstream conduits for other oncogenic drivers, enhancing the process of tumourigenesis in lung adenomas and their transformation to invasive and proliferative adenocarcinoma of the lung [30,31]. This evidence concerns the gene KRAS and lung adenocarcinoma.